LeMaitre Vascular, Inc. (LMAT) Balance Sheet

The sequential increase in total assets from $615.7M in Q4 2025 to $640.5M in Q2 2026 is driven by rising retained earnings and PPE investment, reflecting reinvestment in growth. Equity growth outpacing asset growth suggests improving financial flexibility, with the D/E ratio declining from 0.55 to 0.45 over the past year, per balance sheet data.

The sharp increase in debt coincides with the acquisition of Artegraft and international expansion, suggesting management is using leverage to fund growth rather than operational necessity. Despite the higher leverage, the D/E remains moderate and interest coverage appears ample given strong operating income, but investors should monitor refinancing risk as debt matures.

The increase in PPE aligns with warehouse expansions and sales force buildout, supporting international growth. Goodwill stability suggests no major impairments, but the asset base remains asset-light, with intangibles and goodwill representing a significant portion of total assets, warranting monitoring for potential impairment if growth slows.

Equity expansion is primarily fueled by retained earnings, with no significant share repurchases or dilution, as SBC remains modest. This indicates high-quality equity growth, but the lack of buybacks may suggest management prefers reinvestment and dividends, which is consistent with a conservative capital allocation policy.

The current ratio, though down from 16.49 in Q1 2025, remains extremely high, indicating ample short-term liquidity. Cash levels are stable, but the company's ability to cover short-term obligations is robust, even with increased debt. This liquidity supports ongoing investment in international expansion without straining operations.